<?xml version="1.0" encoding="UTF-8"?>
<ref id="pntd.0007860.ref142">
 <label>142</label>
 <mixed-citation publication-type="journal">
  <name>
   <surname>Covino</surname>
   <given-names>DA</given-names>
  </name>, 
  <name>
   <surname>Purificato</surname>
   <given-names>C</given-names>
  </name>, 
  <name>
   <surname>Catapano</surname>
   <given-names>L</given-names>
  </name>, 
  <name>
   <surname>Galluzzo</surname>
   <given-names>CM</given-names>
  </name>, 
  <name>
   <surname>Gauzzi</surname>
   <given-names>MC</given-names>
  </name>, 
  <name>
   <surname>Vella</surname>
   <given-names>S</given-names>
  </name>, 
  <etal>et al</etal>
  <article-title>APOBEC3G/3A Expression in Human Immunodeficiency Virus Type 1-Infected Individuals Following Initiation of Antiretroviral Therapy Containing Cenicriviroc or Efavirenz</article-title>. 
  <source>Frontiers in immunology</source>. 
  <year>2018</year>;
  <volume>9</volume>:
  <fpage>1839</fpage>
  <pub-id pub-id-type="doi">10.3389/fimmu.2018.01839</pub-id>
  <?supplied-pmid 30135687?>
  <pub-id pub-id-type="pmid">30135687</pub-id>
 </mixed-citation>
</ref>
